Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).

The Product is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon).

This Product is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1708.50 as compared to the previous close of Rs. 1697.30. The total number of shares traded during the day was 2986 in over 452 trades.

The stock hit an intraday high of Rs. 1711.35 and intraday low of 1675.00. The net turnover during the day was Rs. 5081669.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 Pharmaceuticals USFDA Approval ANDA OlopatadineHydrochloride OphthalmicSolution